Mona Ashiya Sells 5,738 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya sold 5,738 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $54.11, for a total value of $310,483.18. Following the sale, the director now directly owns 186,541 shares in the company, valued at approximately $10,093,733.51. This trade represents a 2.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Mona Ashiya also recently made the following trade(s):

• On Friday, March 21st, Mona Ashiya sold 10,011 shares of Disc Medicine stock. The stock was sold at an average price of $54.00, for a total transaction of $540,594.00.
• On Wednesday, March 19th, Mona Ashiya sold 39,656 shares of Disc Medicine stock. The shares were sold at an average price of $54.02, for a total transaction of $2,142,217.12.
• On Wednesday, March 12th, Mona Ashiya sold 83,182 shares of Disc Medicine stock. The shares were sold at an average price of $54.45, for a total transaction of $4,529,259.90.
• On Monday, March 10th, Mona Ashiya sold 202,146 shares of Disc Medicine stock. The stock was sold at an average price of $54.29, for a total value of $10,974,506.34.

Disc Medicine Price Performance

Disc Medicine stock opened at $52.36 on Friday. The stock’s 50 day moving average is $54.64 and its 200 day moving average is $56.10. Disc Medicine, Inc. has a one year low of $25.60 and a one year high of $68.73. The firm has a market cap of $1.81 billion, a P/E ratio of -13.16 and a beta of 0.73.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.08. Equities analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on IRON. HC Wainwright reissued a “buy” rating and set a $118.00 price target on shares of Disc Medicine in a report on Tuesday, January 21st. Wedbush reissued an “outperform” rating and issued a $90.00 target price (up previously from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. TD Cowen started coverage on shares of Disc Medicine in a research note on Thursday, February 27th. They issued a “buy” rating on the stock. Morgan Stanley reiterated an “overweight” rating and set a $85.00 price objective on shares of Disc Medicine in a research report on Friday, March 7th. Finally, Stifel Nicolaus raised their target price on shares of Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Disc Medicine currently has an average rating of “Buy” and a consensus price target of $93.80.

Institutional Trading of Disc Medicine

A number of institutional investors have recently bought and sold shares of the company. Sterling Capital Management LLC raised its position in shares of Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock worth $36,000 after acquiring an additional 503 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Disc Medicine in the fourth quarter worth approximately $40,000. Tower Research Capital LLC TRC increased its holdings in Disc Medicine by 47.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock worth $52,000 after purchasing an additional 266 shares in the last quarter. Quest Partners LLC acquired a new position in Disc Medicine in the third quarter valued at approximately $131,000. Finally, Quantbot Technologies LP bought a new position in shares of Disc Medicine during the 3rd quarter worth approximately $146,000. Institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.